Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. depressive symptoms
Show results for
Products
Software
Training
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Depressive Symptoms Articles & Analysis

17 news found

Ace Therapeutics Accelerates Preclinical Depression Investigation by Providing Depression-Related Behavior Tests

Ace Therapeutics Accelerates Preclinical Depression Investigation by Providing Depression-Related Behavior Tests

With the advancement of biotechnology and biological tools, such as diagnostic technology and animal model development, researchers can further investigate the mechanisms related to depression and thereby develop effective therapies targeting depression. ...

ByAce Therapeutics


Unlock Functional Ingredient Benefits: Lecithin, Omega Fatty Acids, Phytosterol, Antioxidants at Alfa Chemistry

Unlock Functional Ingredient Benefits: Lecithin, Omega Fatty Acids, Phytosterol, Antioxidants at Alfa Chemistry

Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...

ByAlfa Chemistry


Animal Emotional Behavior Tests for Anxiety and Depression Treatment

Animal Emotional Behavior Tests for Anxiety and Depression Treatment

Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of life. Depression is commonly seen in neurodegenerative and neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and autism spectrum disorders. ...

ByProtheragen


CANAQUEST Announces Award of European Cannabinoid Patent

CANAQUEST Announces Award of European Cannabinoid Patent

Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability. ...

ByCanaQuest Medical Corp.


Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in ...

BySage Therapeutics


Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

In patients who completed 1 year of follow-up in both cohorts of the SHORELINE Study (n=407), most had minimal or mild depressive symptoms at study exit as assessed by the Clinical Global Impressions-Severity scale. ...

BySage Therapeutics


Neurolief Announces First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Major Depressive Disorder

Neurolief Announces First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Major Depressive Disorder

The study’s primary endpoint will assess changes in depressive symptoms, from baseline to 8 weeks post-treatment initiation when using Relivion DP, compared to the control group, in subjects suffering from MDD. The severity of depressive symptoms will be assessed by the Hamilton Rating Scale for Depression. ...

ByNeurolief Ltd.


Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion in Greater China and South Korea

Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion in Greater China and South Korea

It is also designed to self-learn and analyze the treatments using AI technology in order to optimize the treatments for patients according to their symptoms. “Because of our commitment to developing the most innovative and effective neuroscience therapies to improve the lives of patients in Asia, NeuroFront is very excited to partner with Neurolief to bring Relivion to ...

ByNeurolief Ltd.


Postpartum Mental Health Awareness - Isabel Healthcare

Postpartum Mental Health Awareness - Isabel Healthcare

During the postpartum period, 85% of women experience some type of mood disturbance. For most part the symptoms are mild and short-lived but in 10-15% the symptoms can become significant and lead to depression. ...

ByIsabel Healthcare


New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

The survey was conducted online by The Harris Poll during August 2021 on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), and in collaboration with the Depression and Bipolar Support Alliance (DBSA), a not-for-profit organization that provides support to people who live with depression and bipolar disorder, as well as to their friends and ...

ByAlkermes


Accenture HealthTech Innovation Challenge Names Eight Finalists

Accenture HealthTech Innovation Challenge Names Eight Finalists

By using the words people say and how they say them, the company has pioneered an artificial intelligence-powered, speech-based vital sign to identify, quantify and manage depression, and anxiety symptoms at scale. Its integrated behavioral health solution aids time-strapped healthcare providers (frontline workers, PCPs, case managers, nurses, etc.) and payers to ...

ByDonisi Health


Q&A with Dr. Carina Carnlöf, lead investigator of the RedHeart study

Q&A with Dr. Carina Carnlöf, lead investigator of the RedHeart study

The direct ECG response of the Coala Heart Monitor contributed to reduced levels of anxiety, depression and symptoms of palpitations. The direct ECG response of the Coala also led to an increased quality of life (HRQOL). ...

ByCoala Life Inc.


RedHeart study proves improved health-related quality of life (HRQOL) using the Coala groundbreaking digital technology

RedHeart study proves improved health-related quality of life (HRQOL) using the Coala groundbreaking digital technology

Coala Life today announced the results of the RedHeart Study where the Coala Heart Monitor (“Coala”) was used to evaluate 821 women with palpitation symptoms over 60 days. Goals were to determine to what degree direct feedback of the underlying heart rhythm, such as provided by the Coala through its instant ECG analysis could help to reduce symptoms ...

ByCoala Life Inc.


How Often should you Take CBD?

How Often should you Take CBD?

A 2015 study found that “CBD has considerable potential as a treatment for multiple anxiety disorders,” including generalized anxiety disorder, panic disorder, and social anxiety disorder. May help improve symptoms of depression. CBD has antidepressant qualities, most likely related to how it interacts with the brain’s serotonin receptors to ...

ByMedcbdx


Nature Fix

Nature Fix

Exposure to nature lowers cortisol, blood pressure, and heart rate. It also reduces the symptoms of dementia and depression while increasing immunity. Since no one can patent or copyright nature, there are no advertising campaigns promoting these findings. ...

ByEco Partners, Inc.


Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson`s patients

Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson`s patients

In addition, patients can suffer associated non-motor symptoms such as difficulty sleeping, memory loss, anxiety and depression. Whilst these symptoms can initially be managed with medication, there is currently no treatment available that effectively prevents disease progression, or that treats the motor and non-motor symptoms ...

ByRenishaw plc


Is Your Office Making You Sick?

Is Your Office Making You Sick?

A study in the November issue of the American Journal of Public Health demonstrated a significant relationship between work stress and depression. Dr. Emma Robertson Blackmore, an assistant professor of psychiatry at the University of Rochester Medical Center and a co-author of the study, says that those with possible symptoms of ...

ByKazan, McClain, Satterley, Lyons, Greenwood & Oberman, A Professional Law Corporation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT